AI Engines For more Details: Perplexity Kagi Labs You
Bronchodilation: Metaproterenol sulfate works by stimulating beta-2 adrenergic receptors in the smooth muscle of the airways. Activation of these receptors leads to relaxation of the bronchial smooth muscle, resulting in bronchodilation. This effect helps to alleviate bronchospasm, improve airflow, and relieve symptoms such as wheezing, shortness of breath, and chest tightness in conditions like asthma and COPD.
Acute Asthma Attacks: Metaproterenol sulfate is often used as a rescue medication to quickly relieve symptoms during acute asthma attacks. Its fast-acting bronchodilator effects help to rapidly open up narrowed airways, allowing for easier breathing and improved oxygenation.
Maintenance Therapy: In addition to its use as a rescue medication, metaproterenol sulfate may also be prescribed as a maintenance therapy for individuals with persistent asthma or COPD. Regular use of the medication helps to prevent or minimize bronchospasm and maintain stable lung function over time.
Exercise-Induced Bronchospasm: Metaproterenol sulfate may be used prophylactically before exercise or physical activity to prevent exercise-induced bronchospasm in individuals with asthma or exercise-induced asthma. By opening up the airways, it can help improve exercise tolerance and reduce the risk of asthma symptoms during physical exertion.
Side Effects: Common side effects associated with metaproterenol sulfate may include palpitations, tremor, nervousness, headache, dizziness, nausea, and throat irritation. These side effects are usually mild and transient. Rare but potentially serious side effects may include cardiac arrhythmias (irregular heart rhythms), hypertension (high blood pressure), hypokalemia (low potassium levels), and paradoxical bronchospasm (worsening of breathing difficulty).
Tolerance and Loss of Effectiveness: Prolonged use of metaproterenol sulfate may lead to tolerance, where the medication becomes less effective over time. This phenomenon may necessitate dose adjustments or the addition of other medications to maintain optimal asthma control.
Contraindications: Metaproterenol sulfate is contraindicated in patients with a known hypersensitivity to the medication or its components. It should be used with caution in patients with certain cardiovascular conditions such as severe hypertension, tachyarrhythmias (rapid heart rhythms), and ischemic heart disease.
Drug Interactions: Metaproterenol sulfate may interact with other medications that affect heart rate or blood pressure, such as beta-blockers, calcium channel blockers, and monoamine oxidase inhibitors (MAOIs). Concurrent use of these medications may potentiate or attenuate the effects of metaproterenol sulfate, necessitating careful monitoring and dose adjustments.
Administration: Metaproterenol sulfate is typically administered via inhalation using a metered-dose inhaler (MDI) or a nebulizer device. Proper inhalation technique is important to ensure optimal drug delivery to the lungs and maximize therapeutic efficacy.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium breve | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Veillonella atypica | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Collinsella | genus | Decreases |
0 | 1 | Ruminococcus | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Veillonella | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Odoribacter | genus | Decreases |
0 | 1 | Bifidobacterium | genus | Decreases |
0 | 1 | Lachnospira | genus | Decreases |
0 | 1 | Parolsenella | genus | Decreases |
0 | 1 | Blautia | genus | Decreases |
0 | 1 | Agathobacter | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Clostridioides | genus | Decreases |
0 | 1 | Enterocloster | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Coprococcus | genus | Decreases |
0 | 1 | Dorea | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
1 | 0 | Ruminococcus bromii | species | Decreases |
1 | 0 | Roseburia hominis | species | Decreases |
1 | 0 | Collinsella aerofaciens | species | Decreases |
1 | 0 | Bifidobacterium longum | species | Decreases |
1 | 0 | Veillonella parvula | species | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Odoribacter splanchnicus | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
1 | 0 | Lachnospira eligens | species | Decreases |
0 | 1 | Bacteroides luhongzhouii | species | Decreases |
0 | 1 | Veillonella rodentium | species | Decreases |
0 | 1 | Bacteroides sp. D2 | species | Decreases |
0 | 1 | Bacteroides sp. M10 | species | Decreases |
0 | 1 | Bifidobacterium breve | species | Decreases |
0 | 1 | Veillonella dispar | species | Decreases |
0 | 1 | Bacteroides sp. DH3716P | species | Decreases |
0 | 1 | Veillonella sp. S12025-13 | species | Decreases |
0 | 1 | Veillonella nakazawae | species | Decreases |
0 | 1 | Parolsenella massiliensis | species | Decreases |
1 | 0 | Bifidobacterium adolescentis | species | Decreases |
1 | 0 | Blautia obeum | species | Decreases |
0 | 1 | Collinsella stercoris | species | Decreases |
0 | 1 | Bacteroides faecium | species | Decreases |
1 | 0 | Agathobacter rectalis | species | Decreases |
0 | 1 | Veillonella rogosae | species | Decreases |
0 | 1 | Parolsenella catena | species | Decreases |
0 | 1 | Bacteroides caecimuris | species | Decreases |
0 | 1 | Veillonella atypica | species | Decreases |
0 | 1 | Parafannyhessea umbonata | species | Decreases |
0 | 1 | Butyricimonas virosa | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
0 | 1 | Coprobacter secundus | species | Decreases |
0 | 1 | Butyricimonas faecalis | species | Decreases |
0 | 1 | Barnesiella viscericola | species | Decreases |
0 | 1 | Alistipes sp. dk3624 | species | Decreases |
0 | 1 | Alistipes megaguti | species | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
1 | 0 | Enterocloster bolteae | species | Decreases |
1 | 0 | [Ruminococcus] torques | species | Decreases |
1 | 0 | Coprococcus comes | species | Decreases |
1 | 0 | Dorea formicigenerans | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.2 | -0.2 | |
ADHD | 2.5 | 0.1 | 24 |
Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.3 | |
Allergic Rhinitis (Hay Fever) | 0.6 | 1 | -0.67 |
Allergies | 2.4 | 1.5 | 0.6 |
Allergy to milk products | 1 | 0.5 | 1 |
Alopecia (Hair Loss) | 0.5 | 0.5 | |
Alzheimer's disease | 2.1 | 3.3 | -0.57 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 0.3 | 1.67 |
Ankylosing spondylitis | 1.4 | 0.7 | 1 |
Anorexia Nervosa | 0.6 | 1.4 | -1.33 |
Antiphospholipid syndrome (APS) | 0 | 0 | |
Asthma | 2.2 | 1.2 | 0.83 |
Atherosclerosis | 1.2 | 0.7 | 0.71 |
Atrial fibrillation | 1.4 | 0.6 | 1.33 |
Autism | 2.6 | 3.1 | -0.19 |
Autoimmune Disease | 0.2 | 0.5 | -1.5 |
Barrett esophagus cancer | 0.3 | 0.3 | |
benign prostatic hyperplasia | 0 | 0.3 | 0 |
Biofilm | 0.3 | 0.3 | |
Bipolar Disorder | 0.6 | 1 | -0.67 |
Brain Trauma | 0.6 | 1.1 | -0.83 |
Breast Cancer | 0 | 0 | |
Cancer (General) | 0.5 | 1.5 | -2 |
Carcinoma | 1.6 | 1.5 | 0.07 |
Celiac Disease | 1 | 2.1 | -1.1 |
Cerebral Palsy | 0.7 | 0.9 | -0.29 |
Chronic Fatigue Syndrome | 2.6 | 2 | 0.3 |
Chronic Kidney Disease | 1.7 | 1.2 | 0.42 |
Chronic Lyme | 0.1 | 0.6 | -5 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.8 | -1.67 |
Chronic Urticaria (Hives) | 0.3 | 0.3 | |
Coagulation / Micro clot triggering bacteria | 0 | 0.7 | 0 |
Cognitive Function | 1.2 | 0.7 | 0.71 |
Colorectal Cancer | 1.4 | 1.3 | 0.08 |
Constipation | 0.7 | 0.4 | 0.75 |
Coronary artery disease | 0.8 | 1.3 | -0.63 |
COVID-19 | 3.7 | 5 | -0.35 |
Crohn's Disease | 2.2 | 2.5 | -0.14 |
Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
cystic fibrosis | 0 | 1 | 0 |
d-lactic acidosis (one form of brain fog) | 0 | 0 | |
deep vein thrombosis | 0.1 | 0.9 | -8 |
Denture Wearers Oral Shifts | 0.5 | 0.5 | |
Depression | 3.6 | 4.5 | -0.25 |
Dermatomyositis | 0.2 | -0.2 | |
Eczema | 0.3 | 0.4 | -0.33 |
Endometriosis | 0.6 | 1.3 | -1.17 |
Eosinophilic Esophagitis | 0.3 | -0.3 | |
Epilepsy | 1 | 0.5 | 1 |
erectile dysfunction | 0.3 | 0.2 | 0.5 |
Fibromyalgia | 0.7 | 0.5 | 0.4 |
Functional constipation / chronic idiopathic constipation | 2.4 | 1.8 | 0.33 |
gallstone disease (gsd) | 0.7 | 0.5 | 0.4 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.5 | -0.67 |
Generalized anxiety disorder | 0.5 | 1.1 | -1.2 |
Gout | 1.5 | 0 | 0 |
Graves' disease | 1.4 | 1.9 | -0.36 |
Gulf War Syndrome | 0.1 | 0.2 | -1 |
Halitosis | 0.5 | 0.5 | |
Hashimoto's thyroiditis | 1.5 | 0.7 | 1.14 |
Heart Failure | 1 | 1 | 0 |
hemorrhagic stroke | 0 | 0 | |
Hidradenitis Suppurativa | 0.4 | 0.3 | 0.33 |
High Histamine/low DAO | 0.3 | 0.5 | -0.67 |
hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
hyperglycemia | 0.5 | 0.5 | 0 |
Hyperlipidemia (High Blood Fats) | 0.6 | 0.4 | 0.5 |
hypersomnia | 0.5 | -0.5 | |
hypertension (High Blood Pressure | 1.5 | 3.1 | -1.07 |
Hypothyroidism | 0.4 | -0.4 | |
Hypoxia | 0.5 | 0.5 | |
IgA nephropathy (IgAN) | 0.6 | 2.4 | -3 |
Inflammatory Bowel Disease | 3 | 4.2 | -0.4 |
Insomnia | 0.7 | 1.6 | -1.29 |
Intelligence | 0.5 | 0.5 | |
Intracranial aneurysms | 0.6 | 0.5 | 0.2 |
Irritable Bowel Syndrome | 3.1 | 2.6 | 0.19 |
ischemic stroke | 1.7 | 0.6 | 1.83 |
Liver Cirrhosis | 3 | 1.4 | 1.14 |
Long COVID | 2.4 | 4.6 | -0.92 |
Low bone mineral density | 0.5 | -0.5 | |
Lung Cancer | 0.5 | 0.4 | 0.25 |
Lymphoma | 0 | 0 | |
Mast Cell Issues / mastitis | 0 | 0.5 | 0 |
ME/CFS with IBS | 0.1 | 0.7 | -6 |
ME/CFS without IBS | 0.2 | 0.5 | -1.5 |
Menopause | 1.6 | 0.3 | 4.33 |
Metabolic Syndrome | 3 | 3.3 | -0.1 |
Mood Disorders | 4.1 | 3.8 | 0.08 |
multiple chemical sensitivity [MCS] | 0.3 | 0.1 | 2 |
Multiple Sclerosis | 2 | 1.8 | 0.11 |
Multiple system atrophy (MSA) | 0.6 | 0.6 | 0 |
myasthenia gravis | 0 | 0.3 | 0 |
neuropathic pain | 0.1 | 2 | -19 |
Neuropathy (all types) | 0.1 | 0.7 | -6 |
neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.4 | 2.6 | -0.08 |
NonCeliac Gluten Sensitivity | 1 | 0.4 | 1.5 |
Obesity | 4.9 | 2.4 | 1.04 |
obsessive-compulsive disorder | 2.2 | 1 | 1.2 |
Osteoarthritis | 0.3 | 0.8 | -1.67 |
Osteoporosis | 1.2 | 0.6 | 1 |
pancreatic cancer | 0.2 | 0.2 | |
Parkinson's Disease | 3.1 | 1.9 | 0.63 |
Polycystic ovary syndrome | 2 | 2 | 0 |
Postural orthostatic tachycardia syndrome | 0.2 | -0.2 | |
Premenstrual dysphoric disorder | 0.7 | 0.7 | |
primary biliary cholangitis | 0.3 | 0.4 | -0.33 |
Primary sclerosing cholangitis | 1.2 | 0.6 | 1 |
Psoriasis | 1.5 | 0.8 | 0.88 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.7 | 2 | 0.85 |
Rosacea | 0.6 | 0.3 | 1 |
Schizophrenia | 3.3 | 1.6 | 1.06 |
scoliosis | 0.1 | 0.6 | -5 |
Sjögren syndrome | 1.2 | 0.8 | 0.5 |
Sleep Apnea | 0.6 | 0.7 | -0.17 |
Slow gastric motility / Gastroparesis | 0.8 | 0.2 | 3 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | 0 |
Stress / posttraumatic stress disorder | 0.8 | 1.3 | -0.63 |
Systemic Lupus Erythematosus | 0.9 | 1.3 | -0.44 |
Tic Disorder | 0.5 | 0.6 | -0.2 |
Tourette syndrome | 0 | 0.3 | 0 |
Type 1 Diabetes | 1.6 | 2.2 | -0.38 |
Type 2 Diabetes | 3.2 | 1.8 | 0.78 |
Ulcerative colitis | 1 | 2.6 | -1.6 |
Unhealthy Ageing | 0.9 | 0.9 | 0 |
Vitiligo | 0.9 | 0.4 | 1.25 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]